insights_auto
Prečo akcie TNG klesli 3,11%?
Preskúmať podrobnejšiechevron_right
TNG:EPA
Transgene SA
0,68 €
arrow_downward
-3,11%(-0,022) 1 d.
8. 10., 17:35:05 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre TNG…
Otvoriť
0,71 €
Vysoká
0,71 €
Nízka
0,68 €
Trh. kap.
190,21 mil.
Priem. obj.
137,31 tis.
Objem
177,22 tis.
Max. za 52 týž.
1,50 €
Min. za 52 týž.
0,68 €
Výnosy na akciu
-0,17 €
Akcie v obehu
278,56 mil.
Počet zamestnancov
160
Otvoriť
0,71 €
Vysoká
0,71 €
Nízka
0,68 €
Trh. kap.
190,21 mil.
Priem. obj.
137,31 tis.
Objem
177,22 tis.
Max. za 52 týž.
1,50 €
Min. za 52 týž.
0,68 €
Výnosy na akciu
-0,17 €
Akcie v obehu
278,56 mil.
Počet zamestnancov
160
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Business Insider Africa
·
pred 37 minútami
What I saw as David Ellison's Skydance rang the opening bell at the New York Stock Exchange
www.marketscreener.com
·
pred 1 hodinou
Wah Fu Announces Corporate Name Change to Wah Fu Education & Technology Group Limited and Nasdaq Ticker “WAFU” Unchanged
Dealroom
·
pred 21 minútami
DarkIris prices $6M Nasdaq offering, among the smallest of its kind
Reuters
·
pred 2 hodinami
Wall St slips as higher yields and oil prices flag inflation risk
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Informácie o subjekte Transgene SA